ADTX Aditxt, Inc.
Mergers ·
Aditxt's subsidiary Ignite Proteomics and the blank-check company Copley Acquisition Corp ended their June 2026 business combination agreement on October 9, 2026. Each side bears its own expenses, and the 8-K gives no reason for the termination.
The Nasdaq Stock Market has filed a Form 25 to remove Aditxt's common stock from listing, dated October 7, 2026. The form does not say why Nasdaq acted, and the company reported $268,852 of cash at March 31, 2026.
The Nasdaq Stock Market said on September 17, 2026 that it will delist the common stock of Aditxt, Inc. The stock was suspended on June 25, 2026 and has not traded on Nasdaq since then.
Aditxt, Inc. said that on August 12, 2026 MDNA Holdings Inc. acquired substantially all of the outstanding shares of its majority-owned subsidiary, Pearsanta, Inc. Pearsanta agreed to pay Aditxt royalties on Net Revenue and two milestone payments of $250,000 each.
Aditxt signed Amendment No. 2 to its secured note purchase agreement with Ignite Proteomics investors on July 16, 2026. The amendment adds an investor, cancels one note and issues two new notes, and leaves the total senior secured principal unchanged.
Aditxt sold $769,230.77 of additional senior secured convertible notes for $500,000.00 in cash, and it reported $268,852 of cash at March 31, 2026. The filing does not name the investors.
Aditxt, Inc. signed a definitive business combination agreement for Ignite Proteomics, LLC, its 100%-owned subsidiary, at an implied equity value of approximately $150 million. Ignite would become an independent public company through a newly formed holding company.
Aditxt has issued senior secured convertible notes that combine about $725,000 in new cash with earlier notes consolidated into them, at a 35% original issue discount. The company held $268,852 in cash at March 31, 2026.
Aditxt, Inc. received a Nasdaq letter on May 27, 2026 citing stockholders' equity of $(35,174,386) for the period ended March 31, 2026. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 11, 2026.
Aditxt, Inc. said it will effect a 1-for-27 reverse split of its common stock at the opening of trading on May 18, 2026. The company says the split is primarily intended to bring it into compliance with Nasdaq's minimum bid price requirement.
The company filed a late-filing notice on November 15, 2024. It plans to file the report no later than 5 days after the original due date.
Aditxt, Inc. is a Delaware corporation headquartered in Mountain View, California. Its subsidiary Adimune, Inc. leads its immune modulation therapeutic programs. Adimune's proprietary Apoptotic DNA Immunotherapy (ADI) is a nucleic acid-based approach designed to induce tolerance to specific tissues, with the aim of prolonging the survival of transplanted organs and reducing the need for immune suppression. Its first candidate, ADI-100, is designed to tolerize against glutamic acid decarboxylase, an antigen implicated in type-1 diabetes, psoriasis and autoimmune diseases of the central nervous system. All preclinical studies for ADI-100 have been completed. The ADI technology is licensed exclusively from Loma Linda University. Adimune has a clinical trial agreement with the Mayo Clinic, and a human trial in Stiff Person Syndrome is expected to get underway in 2026 with enrollment of 10-20 patients. Clinical trials planned in Germany are being managed by a contract research organization. Another subsidiary, Pearsanta, is pioneering molecular tests based on mitochondrial DNA for early cancer detection.
| Product or program | What it is | Stage |
|---|---|---|
| ADI-100 | Immune tolerance DNA therapy targeting GAD for autoimmune diseases | Preclinical studies completed; human trial expected to begin in 2026 |
| Pearsanta molecular tests | Mitochondrial DNA-based molecular tests for early cancer detection |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $3,195 | $133,985 |
| Research and development | $3.2 million | $10.9 million |
| Net income (loss) | -$43.1 million | -$40.4 million |
| Cash from operations | -$25.7 million | -$16.8 million |
| Cash and equivalents | $3.2 million | $833,031 |
Our latest story on this, dated May 14, 2026: "Aditxt plans 1-for-27 reverse stock split effective May 18". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 7, 2026: "Nasdaq files to remove Aditxt common stock from listing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 22, 2026: "Aditxt adds $769,230.77 in senior secured convertible notes". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Nov 15, 2024: "Aditxt delays quarterly report for period ended September 30, 2024". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 15, 2026: "Aditxt unit Ignite Proteomics and Copley Acquisition Corp end SPAC merger deal". The story links the filing or release it is based on. Read the story.
Aditxt, Inc. trades under the ticker ADTX on OTC.
Aditxt, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Aditxt, Inc. is 1726711. Its filings are on SEC EDGAR.
815,921 shares as of 2026-05-20, per the cover page of its 10-Q filed 2026-05-20.
Our directory records Aditxt, Inc. under United States.
Our directory classifies Aditxt, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Aditxt, Inc. is US0070258696.
aibio.space lists Aditxt, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Aditxt, Inc. is a Delaware corporation headquartered in Mountain View, California. Its subsidiary Adimune, Inc. leads its immune modulation therapeutic programs.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,1.02,9.01). Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 424B5. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,2.03,3.02,5.03,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio